Physician

Rebecca Rose Callis, M.D.

According to 2025 Medicare claims, Rebecca Callis, M.D. (NPI: 1659597755) practices rheumatology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Boone, KY. This provider's primary affiliated billing organization is NORTHERN KENTUCKY ARTHRITIS RHEUMATOLOGY AND INFUSION LLC (NPI: 1598379885; TIN: 852696217) and primary practice location at 41042-1618. Callis is affiliated with the Healthcare Solutions Network (ACO ID: A3283) and Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Callis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 220 traditional Medicare patients, billed 38,174 HCPCS/CPT codes, and received $803,086 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,260 prescription claims across 296 beneficiaries totaling $1,125,068 in drug costs, led by Octagam (Immun Globg(Igg)/Malt/Iga Ov50). Open Payments data shows 114 records totaling $40,341. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $4,108,414 to $803,086. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,490,608 and ending at $1,125,068. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	518	138,216	$4,108,414
2016	371	92,157	$2,609,005
2017	240	57,547	$1,565,407
2018	352	67,165	$1,569,777
2019	388	86,580	$1,808,697
2020	74	2,900	$68,551
2021	159	17,699	$322,438
2022	207	26,060	$701,443
2023	206	32,159	$767,606
2024	220	38,174	$803,086

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	597	5,534	$1,490,608
2016	540	5,504	$1,868,886
2017	400	3,517	$1,367,541
2018	489	3,858	$1,644,504
2019	556	4,526	$2,673,154
2020	113	397	$49,491
2021	179	1,187	$141,673
2022	243	2,152	$569,048
2023	254	2,107	$834,831
2024	296	2,260	$1,125,068

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	54	101	$126
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	37	37	$119
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	188	474	$89
96413	Administration of chemotherapy into vein, 1 hour or less	43	283	$84
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	33	141	$46

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	12	336	$305,963
Cosentyx Sensoready (2 Pens)	Secukinumab	19	532	$142,326
Enbrel Sureclick	Etanercept	15	420	$109,262
Humira(Cf) Pen	Adalimumab	15	420	$101,763
Rinvoq	Upadacitinib	11	330	$69,608

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	114	$40,341	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rebecca Rose Callis, M.D.?

Tedicare shows public-source Medicare data for Rebecca Rose Callis, M.D. (NPI 1659597755), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rebecca Rose Callis, M.D. have ACO affiliation data?

Rebecca Rose Callis, M.D. is shown with ACO affiliation data for Healthcare Solutions Network (MSSP, ACO ID A3283) and Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Rebecca Rose Callis, M.D.?

Rebecca Rose Callis, M.D. is linked to NORTHERN KENTUCKY ARTHRITIS RHEUMATOLOGY AND INFUSION LLC (billing NPI 1598379885) in the available physician profile data.

Does Rebecca Rose Callis, M.D. have Open Payments data?

Rebecca Rose Callis, M.D. has 114 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.